She received her PhD from the University of Oklahoma and completed a postdoctoral study at the National Human Genome Research Institute in Bethesda, MD under the direction of Dr. Francis Collins. Dr. Crabtree worked in drug development at Wyeth Pharmaceuticals for 6 years before returning to academic science at LSUHSC. Dr. Crabtree’s research focuses on mechanisms of tumorigenesis in hormone-responsive and neuroendocrine-derived cancers. Specifically, ER+ breast cancer and neuroendocrine cancers of the endocrine pancreas, parathyroid and skin using a variety of in vitro and in vivo models to understand genetic, epigenetic and non-genetic contributions. The Crabtree laboratory studies the role of the histone demethylase protein RBP2/KDM5A pancreatic NETs and Notch signaling in ER+ breast cancer.